NASDAQ:GLYC - GlycoMimetics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.50
  • Forecasted Upside: 911.90 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.84
▼ -0.04 (-4.55%)

This chart shows the closing price for GLYC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GlycoMimetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GLYC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLYC

Analyst Price Target is $8.50
▲ +911.90% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for GlycoMimetics in the last 3 months. The average price target is $8.50, with a high forecast of $13.00 and a low forecast of $4.00. The average price target represents a 911.90% upside from the last price of $0.84.

This chart shows the closing price for GLYC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in GlycoMimetics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/16/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/4/2022HC WainwrightLower Price TargetBuy$14.00 ➝ $13.00Low
11/12/2021Jefferies Financial GroupUpgradeHold ➝ Buy$3.00 ➝ $4.00High
11/2/2021HC WainwrightReiterated RatingBuyHigh
5/3/2021Stifel NicolausBoost Price TargetBuy$8.00 ➝ $9.00High
3/10/2021HC WainwrightReiterated RatingBuyMedium
12/8/2020Roth CapitalBoost Price TargetPositive ➝ Buy$9.00 ➝ $15.00Medium
7/31/2020HC WainwrightLower Price TargetBuy$16.00 ➝ $15.00Medium
5/1/2020HC WainwrightReiterated RatingBuy$16.00High
3/27/2020CowenInitiated CoverageBuyLow
3/2/2020HC WainwrightLower Price TargetBuy$18.00 ➝ $16.00High
11/21/2019Roth CapitalLower Price Target$12.00 ➝ $9.00High
11/14/2019Roth CapitalInitiated CoverageBuy$12.00 ➝ $12.00Medium
11/8/2019HC WainwrightReiterated RatingBuy$18.00High
11/7/2019Piper Jaffray CompaniesReiterated RatingNeutral$6.00 ➝ $5.00High
8/5/2019HC WainwrightLower Price TargetBuy$23.00 ➝ $18.00High
8/5/2019Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
8/5/2019SunTrust BanksDowngradeBuy ➝ Hold$23.00 ➝ $5.00High
8/4/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$20.00 ➝ $6.00High
5/3/2019CowenReiterated RatingBuyMedium
4/12/2019HC WainwrightReiterated RatingBuy$23.00Low
4/12/2019Piper Jaffray CompaniesInitiated CoverageOverweight$20.00High
12/18/2018HC WainwrightInitiated CoverageBuy ➝ Buy$24.00Low
11/5/2018Roth CapitalSet Price TargetBuy$35.00High
8/13/2018CowenReiterated RatingBuyMedium
8/12/2018Stifel NicolausReiterated RatingBuy$24.00Medium
3/7/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$23.00 ➝ $25.00Medium
2/8/2018Roth CapitalSet Price TargetBuy$35.00Medium
12/20/2017Jefferies Financial GroupReiterated RatingBuy$21.00Medium
12/14/2017Stifel NicolausReiterated RatingBuy$23.00Medium
12/12/2017SunTrust BanksBoost Price TargetBuy$32.00High
12/6/2017CowenReiterated RatingBuyLow
10/26/2017Jefferies Financial GroupReiterated RatingBuy$16.00N/A
10/23/2017Roth CapitalInitiated CoverageBuy$25.00N/A
10/4/2017SunTrust BanksReiterated RatingBuy$21.00N/A
(Data available from 8/16/2017 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/17/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/16/2022
  • 0 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/18/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/17/2022
  • 2 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/17/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/16/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/16/2022
  • 6 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/15/2022

Current Sentiment

  • 6 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
GlycoMimetics logo
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $0.84
Low: $0.80
High: $0.91

50 Day Range

MA: $0.68
Low: $0.54
High: $0.90

52 Week Range

Now: $0.84
Low: $0.51
High: $2.50

Volume

355,750 shs

Average Volume

149,125 shs

Market Capitalization

$44.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.85

Frequently Asked Questions

What sell-side analysts currently cover shares of GlycoMimetics?

The following Wall Street sell-side analysts have issued research reports on GlycoMimetics in the last twelve months: HC Wainwright, Jefferies Financial Group Inc., and StockNews.com.
View the latest analyst ratings for GLYC.

What is the current price target for GlycoMimetics?

2 Wall Street analysts have set twelve-month price targets for GlycoMimetics in the last year. Their average twelve-month price target is $8.50, suggesting a possible upside of 911.9%. HC Wainwright has the highest price target set, predicting GLYC will reach $13.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $4.00 for GlycoMimetics in the next year.
View the latest price targets for GLYC.

What is the current consensus analyst rating for GlycoMimetics?

GlycoMimetics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GLYC will outperform the market and that investors should add to their positions of GlycoMimetics.
View the latest ratings for GLYC.

What other companies compete with GlycoMimetics?

How do I contact GlycoMimetics' investor relations team?

GlycoMimetics' physical mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company's listed phone number is (240) 243-1201 and its investor relations email address is [email protected] The official website for GlycoMimetics is www.glycomimetics.com. Learn More about contacing GlycoMimetics investor relations.